Based on these, we propose the hypothesis that QB can reduce the inflammatory response and delay disease progression in SLE combined with atherosclerosis by inhibiting the HMGB1/TLR4/MyD88 pathway. Here, MYD88 is linked to systemic lupus erythematosus.